JP2018517410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517410A5 JP2018517410A5 JP2017562027A JP2017562027A JP2018517410A5 JP 2018517410 A5 JP2018517410 A5 JP 2018517410A5 JP 2017562027 A JP2017562027 A JP 2017562027A JP 2017562027 A JP2017562027 A JP 2017562027A JP 2018517410 A5 JP2018517410 A5 JP 2018517410A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- domain
- nucleic acid
- protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1509413.9 | 2015-06-01 | ||
| GBGB1509413.9A GB201509413D0 (en) | 2015-06-01 | 2015-06-01 | Fusion protein |
| PCT/GB2016/051576 WO2016193696A1 (en) | 2015-06-01 | 2016-05-31 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086590A Division JP2020115898A (ja) | 2015-06-01 | 2020-05-18 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517410A JP2018517410A (ja) | 2018-07-05 |
| JP2018517410A5 true JP2018517410A5 (https=) | 2019-05-09 |
| JP6833727B2 JP6833727B2 (ja) | 2021-02-24 |
Family
ID=53677545
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562027A Active JP6833727B2 (ja) | 2015-06-01 | 2016-05-31 | 細胞 |
| JP2020086590A Withdrawn JP2020115898A (ja) | 2015-06-01 | 2020-05-18 | 細胞 |
| JP2022032551A Withdrawn JP2022066380A (ja) | 2015-06-01 | 2022-03-03 | 細胞 |
| JP2024137629A Pending JP2024149818A (ja) | 2015-06-01 | 2024-08-19 | 細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020086590A Withdrawn JP2020115898A (ja) | 2015-06-01 | 2020-05-18 | 細胞 |
| JP2022032551A Withdrawn JP2022066380A (ja) | 2015-06-01 | 2022-03-03 | 細胞 |
| JP2024137629A Pending JP2024149818A (ja) | 2015-06-01 | 2024-08-19 | 細胞 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11345734B2 (https=) |
| EP (2) | EP3303568B1 (https=) |
| JP (4) | JP6833727B2 (https=) |
| KR (1) | KR102275460B1 (https=) |
| CN (1) | CN107667170B (https=) |
| AU (1) | AU2016272457B2 (https=) |
| BR (1) | BR112017023190A2 (https=) |
| CA (1) | CA2986956C (https=) |
| CL (1) | CL2017003057A1 (https=) |
| DK (1) | DK3303568T3 (https=) |
| ES (1) | ES2791338T3 (https=) |
| GB (1) | GB201509413D0 (https=) |
| HU (1) | HUE050132T2 (https=) |
| IL (1) | IL255594B (https=) |
| MX (1) | MX383118B (https=) |
| PL (1) | PL3303568T3 (https=) |
| PT (1) | PT3303568T (https=) |
| RU (1) | RU2729158C2 (https=) |
| WO (1) | WO2016193696A1 (https=) |
| ZA (1) | ZA201707334B (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| RU2766690C2 (ru) | 2015-07-28 | 2022-03-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения |
| WO2017123559A2 (en) * | 2016-01-11 | 2017-07-20 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| GB201621889D0 (en) * | 2016-12-21 | 2017-02-01 | Autolus Ltd | Cell |
| WO2018157000A1 (en) * | 2017-02-23 | 2018-08-30 | Olema Pharmaceuticals, Inc. | Compositions and methods for regulating immune system activity |
| EP3589647A1 (en) * | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| GB201707783D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| JP7132249B2 (ja) * | 2017-05-15 | 2022-09-06 | オートラス リミテッド | キメラ抗原受容体（ｃａｒ）を含む細胞 |
| TWI731268B (zh) * | 2017-09-29 | 2021-06-21 | 財團法人國家衛生研究院 | 可增強抗腫瘤與抗病毒ｔ細胞存活與其功能性之方法與組合物 |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| WO2019118518A2 (en) * | 2017-12-11 | 2019-06-20 | Senti Biosciences, Inc. | Inducible cell receptors for cell-based therapeutics |
| EP3810753A1 (en) * | 2018-06-19 | 2021-04-28 | Autolus Limited | Cell |
| CN109294982B (zh) * | 2018-09-30 | 2020-11-06 | 北京鼎成肽源生物技术有限公司 | 一种rff2细胞 |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| CA3121911A1 (en) * | 2018-12-06 | 2020-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatable cell surface receptors and related compositions and methods |
| GB201820157D0 (en) * | 2018-12-11 | 2019-01-23 | Imperial Innovations Ltd | Method of treatment |
| US20220133791A1 (en) | 2019-01-23 | 2022-05-05 | Miltenyi Biotec B.V. & Co. KG | A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| WO2020190771A1 (en) * | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| AU2020268388A1 (en) * | 2019-05-07 | 2021-12-02 | Modernatx, Inc. | Polynucleotides for disrupting immune cell activity and methods of use thereof |
| CN118165120A (zh) * | 2019-07-22 | 2024-06-11 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| JP7831937B2 (ja) | 2019-09-03 | 2026-03-17 | クリエイト・メディシンズ，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| US20220401537A1 (en) * | 2019-09-16 | 2022-12-22 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| JP7773976B2 (ja) * | 2019-10-23 | 2025-11-20 | スティヒティング ヘット ネーデルランズ カンケル インスティテュート－アントニ ファン レーウェンフーク ジーケンハウス | 免疫細胞制御用キメラポリペプチド |
| WO2021096868A1 (en) * | 2019-11-12 | 2021-05-20 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| EP4073103A1 (en) | 2019-12-11 | 2022-10-19 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| EP4100027A1 (en) | 2020-02-04 | 2022-12-14 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| US12286465B2 (en) | 2020-05-28 | 2025-04-29 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains |
| CN115867294A (zh) | 2020-06-04 | 2023-03-28 | 凯瑞斯马治疗公司 | 嵌合抗原受体的新型构建体 |
| CA3188143A1 (en) * | 2020-06-25 | 2021-12-30 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| AU2021328478A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| KR102859550B1 (ko) | 2020-08-20 | 2025-09-16 | 에이투 바이오쎄라퓨틱스, 인크. | Ceacam 양성 암을 치료하기 위한 조성물 및 방법 |
| WO2022093741A1 (en) * | 2020-10-26 | 2022-05-05 | Research Development Foundation | Mutant proteases and uses thereof |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| US20230405047A1 (en) | 2020-11-09 | 2023-12-21 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
| CN118703444A (zh) * | 2021-01-22 | 2024-09-27 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体改造的nk细胞及其制备方法与应用 |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| JP2023008482A (ja) | 2021-07-06 | 2023-01-19 | 日本たばこ産業株式会社 | たばこ製品の香味料担持構成部材及びこの製造方法 |
| WO2023044304A1 (en) * | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| EP4426341A4 (en) * | 2021-11-04 | 2025-10-01 | Dana Farber Cancer Inst Inc | DEVELOPMENT OF INDUCIBLE CHIMERIC CLUSTERED ANTIGEN RECEPTOR (CCAR) CONSTRUCTS |
| EP4602171A1 (en) | 2022-10-15 | 2025-08-20 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| CN119331105B (zh) * | 2024-09-03 | 2025-10-28 | 中国人民解放军空军军医大学 | 靶向多种免疫检查点的通用多肽-protac及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| AU723595B2 (en) * | 1995-06-07 | 2000-08-31 | University Of Pennsylvania | Methods of inhibiting phagocytosis |
| AU2053197A (en) * | 1996-02-23 | 1997-09-10 | Ariad Pharmaceuticals, Inc. | Cell-based assay |
| US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| US7060506B2 (en) | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| GB0224442D0 (en) * | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| CN102070719A (zh) * | 2010-11-24 | 2011-05-25 | 中国人民解放军第四军医大学 | 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47 |
| WO2015142314A1 (en) * | 2013-03-15 | 2015-09-24 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| US20160296562A1 (en) * | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| MY167722A (en) * | 2014-10-09 | 2018-09-21 | Univ Yamaguchi | Car expression vector and car-expressing t cells |
| GB201620070D0 (en) | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
-
2015
- 2015-06-01 GB GBGB1509413.9A patent/GB201509413D0/en not_active Ceased
-
2016
- 2016-05-31 ES ES16726416T patent/ES2791338T3/es active Active
- 2016-05-31 KR KR1020177033957A patent/KR102275460B1/ko active Active
- 2016-05-31 WO PCT/GB2016/051576 patent/WO2016193696A1/en not_active Ceased
- 2016-05-31 AU AU2016272457A patent/AU2016272457B2/en active Active
- 2016-05-31 RU RU2017145074A patent/RU2729158C2/ru active
- 2016-05-31 DK DK16726416.7T patent/DK3303568T3/da active
- 2016-05-31 CN CN201680030192.8A patent/CN107667170B/zh active Active
- 2016-05-31 EP EP16726416.7A patent/EP3303568B1/en active Active
- 2016-05-31 MX MX2017014630A patent/MX383118B/es unknown
- 2016-05-31 PL PL16726416T patent/PL3303568T3/pl unknown
- 2016-05-31 EP EP20166710.2A patent/EP3730609A1/en not_active Withdrawn
- 2016-05-31 BR BR112017023190A patent/BR112017023190A2/pt not_active Application Discontinuation
- 2016-05-31 HU HUE16726416A patent/HUE050132T2/hu unknown
- 2016-05-31 PT PT167264167T patent/PT3303568T/pt unknown
- 2016-05-31 US US15/577,378 patent/US11345734B2/en active Active
- 2016-05-31 CA CA2986956A patent/CA2986956C/en active Active
- 2016-05-31 JP JP2017562027A patent/JP6833727B2/ja active Active
-
2017
- 2017-10-27 ZA ZA2017/07334A patent/ZA201707334B/en unknown
- 2017-11-12 IL IL255594A patent/IL255594B/en active IP Right Grant
- 2017-11-30 CL CL2017003057A patent/CL2017003057A1/es unknown
-
2020
- 2020-05-18 JP JP2020086590A patent/JP2020115898A/ja not_active Withdrawn
-
2022
- 2022-03-03 JP JP2022032551A patent/JP2022066380A/ja not_active Withdrawn
-
2024
- 2024-08-19 JP JP2024137629A patent/JP2024149818A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517410A5 (https=) | ||
| RU2017145074A (ru) | Клетка | |
| EP3749338B1 (en) | Humanized bcma antibody and bcma-car-t cells | |
| Shiratori et al. | Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor | |
| CN114746438A (zh) | 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂 | |
| JP2016538855A5 (https=) | ||
| JP2016538854A5 (https=) | ||
| JP2018523484A5 (https=) | ||
| WO2018193231A1 (en) | Cell | |
| JP7602803B2 (ja) | Ｃｄ１４７キメラ抗原受容体および使用の方法 | |
| WO2020190771A1 (en) | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy | |
| JP2019535292A5 (https=) | ||
| JP7728477B2 (ja) | 抗ｒｏｒ１抗体及びｒｏｒ１を標的とする操作された細胞 | |
| JP6842688B2 (ja) | キメラ抗原受容体 | |
| WO2025134168A1 (en) | Genetically modified immune cells for the treatment of tumors and autoimmune diseases | |
| US12612443B2 (en) | Cell | |
| WO2025016450A1 (en) | Combination of cldn18.2 and gucy2c targeted antagonist therapy | |
| CN119301257A (zh) | 用于工程化改造固有样淋巴细胞的方法 | |
| HK40075954A (en) | Disrupting tumor tissues by targeting fibroblast activation protein (fap) | |
| GB2569692A (en) | T cell antigen receptor chimera | |
| BR122025000772A2 (pt) | Célula | |
| NZ737662B2 (en) | Cell |